HIC1 and gastric cancer: Furthermore, to further elucidate the impact of PD‐L1 antibody on the therapeutic efficacy of the combined treatment involving LV‐HIC1 or LV‐shHIC1, MFC‐challenged subcutaneous GC model in 615‐line mice (immunocompromised) was constructed.